Multiplex Testing for Evaluation of Breast Cancer Risk, Longitudinal Study

Abramson Cancer Center at Penn Medicine1 site in 1 country350 target enrollmentJuly 2014

ConditionsBRCA1/2 Negative

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: BRCA1/2 Negative
Sponsor: Abramson Cancer Center at Penn Medicine
Enrollment: 350
Locations: 1
Primary Endpoint: Completion of questionnaires
Status: Completed
Last Updated: 6 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The overall goal of the proposed research is to evaluate the uptake of testing and longitudinal risks and benefits of multiplex testing for cancer susceptibility in BRCA1/2 negative patients. This model will inform the selection of the outcomes and potential mediators and moderators of these outcomes, to inform the debate over utility, risks, and benefits of clinical incorporation of multiplex testing for breast cancer susceptibility.

Registry

clinicaltrials.gov

Start Date

July 2014

End Date

October 2018

Last Updated

6 years ago

Study Type

Interventional

Study Design

Single Group